Conatumumab

Conatumumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	TRAIL-R2 (CD262)
Clinical data
Other names	anti-TRAIL receptor 2 monoclonal antibody, AMG-655
ATC code	none;
Identifiers
CAS Number	896731-82-1 ;
ChemSpider	none;
UNII	1P48L61KM0 ;
KEGG	D09329 ;
Chemical and physical data
Formula	C6466H10006N1730O2024S40
Molar mass	145645.66 g·mol−1
	(what is this?) (verify)

Last updated August 16, 2025

Conatumumab (originally AMG-655) is a monoclonal antibody developed for the treatment of cancer. It is a fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2, death receptor 5, TNFRSF10B) with potential antineoplastic activity.^[1]^[2] Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin.^[3]^[4]

The drug was developed by Amgen Inc. In 2008, Takeda licensed the drug from Amgen for development in Japan, but discontinued development in 2011.

References

↑ Rosevear HM, Lightfoot AJ, Griffith TS (June 2010). "Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer". Current Opinion in Investigational Drugs. 11 (6). London, England: 688–98. PMID 20496264.
↑ Bajaj M, Heath EI (November 2011). "Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults". Expert Opinion on Biological Therapy. 11 (11): 1519–24. doi:10.1517/14712598.2011.610788. PMID 21877997. S2CID 28520935.
↑ Statement On A Nonproprietary Name Adopted By The USAN Council – Conatumumab, American Medical Association.
↑ National Cancer Institute: Definition of conatumomab

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[Rosevear_2010-1] Rosevear HM, Lightfoot AJ, Griffith TS (June 2010). "Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer". Current Opinion in Investigational Drugs. 11 (6). London, England: 688–98. PMID 20496264.

[Bajaj_2011-2] Bajaj M, Heath EI (November 2011). "Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults". Expert Opinion on Biological Therapy. 11 (11): 1519–24. doi:10.1517/14712598.2011.610788. PMID 21877997. S2CID 28520935.

[3] Statement On A Nonproprietary Name Adopted By The USAN Council – Conatumumab, American Medical Association.

[4] National Cancer Institute: Definition of conatumomab

[1]

[2]

[3]

[4]